4.5 Article

Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium

Journal

HUMAN MOLECULAR GENETICS
Volume 20, Issue 16, Pages 3289-3303

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/hmg/ddr228

Keywords

-

Funding

  1. European Community [223175, HEALTH-F2-2009-223175]
  2. CR-UK [C1287/A10118, C1287/A7497, C1287/A12014, C8197/A10865]
  3. European Union [BM0606, LSHC-CT-2003-503297]
  4. National Health and Medical Research Council of Australia [199600]
  5. New South Wales Cancer Council
  6. Victorian Health Promotion Foundation (Australia)
  7. National Cancer Institute, National Institutes of Health [RFA-CA-06-503, CA-06-503, CA-58860]
  8. Dutch Cancer Society [NKI 2001-2423, 2007-3839, DDHK 2004-3124]
  9. Dutch National Genomics Initiative
  10. University of Erlangen
  11. Dr Mildred Scheel Stiftung of the Deutsche Krebshilfe e.V
  12. Dietmar-Hopp Foundation
  13. Helmholtz Society
  14. Chief Physician Johan Boserup and Lise Boserup Fund
  15. Danish Medical Research Council
  16. Copenhagen University Hospital, Herlev Hospital
  17. Red Tematica de Investigacion Cooperativa en Cancer
  18. Asociacion Espanola Contra Cancer
  19. Fondo de Investigacion Sanitario [PI081120, PI081583]
  20. Federal Ministry of Education and Research (BMBF) Germany [01KW9975/5, 01KW9976/8, 01KW9977/0, 01KW0114]
  21. Deutsche Krebshilfe e.V [70492, 70-2892-BR I]
  22. Hannover Medical School
  23. Helsinki University Central Hospital
  24. Academy of Finland [110663]
  25. Finnish Cancer Society
  26. Sigrid Juselius Foundation
  27. Swedish Cancer Society
  28. Gustav V Jubilee Foundation
  29. Bert von Kantzow Foundation
  30. Kuopio University
  31. University of Kuopio
  32. EVO research funding of Vaasa Hospital District
  33. National Breast Cancer Foundation
  34. National Health and Medical Research Council (NHMRC) [145684, 288704, 454508, 209057, 251533, 396414, 504711, 504715]
  35. Queensland Cancer Fund
  36. Cancer Council of New South Wales
  37. Cancer Council of Victoria
  38. Cancer Council of Tasmania
  39. Cancer Council of South Australia
  40. Cancer Foundation of Western Australia
  41. US Army Medical Research and Material Command [DAMD17-01-1-0729]
  42. Cancer Council Tasmania and Cancer Foundation of Western Australia
  43. Stichting tegen Kanker [232-2008]
  44. Hamburg Cancer Society
  45. German Cancer Research Center
  46. German Federal Ministry of Education and Research [01KH0402]
  47. National Institutes of Health [R01 CA122340, R01-CA63464, R37-CA54281]
  48. NCI Specialized Program of Research Excellence (SPORE) in breast cancer [P50 CA116201]
  49. Cancer Council Victoria
  50. Norwegian Research council [155218/V40, 175240/S10, 181600/V11]
  51. Swizz Bridge Award
  52. Cancer Care Ontario [U01 CA69467]
  53. Northern California Cancer Center [U01 CA69417]
  54. University of Melbourne [U01 CA69638]
  55. National Cancer Institute, Department of Health and Human Services, USA
  56. Agency for Science, Technology and Research of Singapore (A*STAR)
  57. US National Institute of Health (NIH)
  58. Susan G. Komen Breast Cancer Foundation
  59. Breast Cancer Campaign
  60. Yorkshire Cancer Research
  61. Cancer Research UK [C1287/A10118, C490/A1102, C8197/A10123, C490/A10119, C490/A11020]
  62. NIHR Cambridge Biomedical Research Centre
  63. Cambridge Experimental Cancer Medicine Centre
  64. National Cancer Institute Thailand
  65. Institute of Biomedical Sciences, Academia Sinica, National Sciences Counciland Taiwan Biobank
  66. Lon V Smith Foundation [LVS-39420]
  67. [PBZ_KBN_122/P05/2004]
  68. Cancer Research UK [11022, 10118] Funding Source: researchfish
  69. The Francis Crick Institute
  70. Cancer Research UK [10124] Funding Source: researchfish

Ask authors/readers for more resources

Breast cancers demonstrate substantial biological, clinical and etiological heterogeneity. We investigated breast cancer risk associations of eight susceptibility loci identified in GWAS and two putative susceptibility loci in candidate genes in relation to specific breast tumor subtypes. Subtypes were defined by five markers (ER, PR, HER2, CK5/6, EGFR) and other pathological and clinical features. Analyses included up to 30 040 invasive breast cancer cases and 53 692 controls from 31 studies within the Breast Cancer Association Consortium. We confirmed previous reports of stronger associations with ER+ than ER- tumors for six of the eight loci identified in GWAS: rs2981582 (10q26) (P-heterogeneity = 6.1 x 10(-18)), rs3803662 (16q12) (P = 3.7 x 10(-5)), rs13281615 (8q24) (P = 0.002), rs13387042 (2q35) (P = 0.006), rs4973768 (3p24) (P = 0.003) and rs6504950 (17q23) (P = 0.002). The two candidate loci, CASP8 (rs1045485, rs17468277) and TGFB1 (rs1982073), were most strongly related with the risk of PR negative tumors (P = 5.1 x 10(-6) and P = 4.1 x 10(-4), respectively), as previously suggested. Four of the eight loci identified in GWAS were associated with triple negative tumors (P <= 0.016): rs3803662 (16q12), rs889312 (5q11), rs3817198 (11p15) and rs13387042 (2q35); however, only two of them (16q12 and 2q35) were associated with tumors with the core basal phenotype (P <= 0.002). These analyses are consistent with different biological origins of breast cancers, and indicate that tumor stratification might help in the identification and characterization of novel risk factors for breast cancer subtypes. This may eventually result in further improvements in prevention, early detection and treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available